The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

Taszkun, Iwona

doi:10.2478/v10181-010-0005-4

Cited by 6 publications

(7 citation statements)

References 9 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of CADLI over other scales was based on its speed, simplicity and responsiveness to change. On this basis, the reduction in skin lesion severity and the percentage of dogs whose lesion scores improved ≥50% were found here to be similar to that of other therapies for cAD (see Table S1 in Supporting information) . Moreover, the mean percentage reduction observed here is notably higher than that previously recorded for a placebo .…”

Section: Discussionsupporting

confidence: 83%

Efficacy of ultra‐micronized palmitoylethanolamide in canine atopic dermatitis: an open‐label multi‐centre study

Noli¹,

Valle

Miolo

et al. 2015

Veterinary Dermatology

View full text Add to dashboard Cite

Background -Palmitoylethanolamide is a naturally occurring bioactive lipid, produced on-demand by damageexposed cells. Palmitoylethanolamide is documented to counteract inflammation, itch and pain.Objective -The aim of this 8-week study was to evaluate the efficacy of oral ultra-micronized palmitoylethanolamide (PEA-um) in dogs with moderate atopic dermatitis.Animals -Clinicians from 39 veterinary clinics enrolled 160 dogs with nonseasonal atopic dermatitis and moderate pruritus.Methods -This was a multi-centre open-label study. On days 0 (D0) and 56 (D56), owners evaluated pruritus with a Visual Analog Scale (VAS) and completed a validated Quality of Life (QoL) questionnaire. Veterinarians assessed the severity of skin lesions using the Canine Atopic Dermatitis Lesion Index (CADLI).Results -Mean pruritus VAS score decreased from 5.7 AE 0.08 cm (range 3.8-7.9 cm) to 3.63 AE 0.19 cm (range 0.1-9.2 cm) (P < 0.0001). At D56, 58% of dogs showed a greater than 2 cm reduction from baseline and 30% showed an absent-to-very mild pruritus (VAS ≤ 2 cm). Mean total CADLI at D56 decreased significantly (P < 0.0001); in 62% of dogs this score reached a value in the remission range (≤5). Mean total QoL score was significantly decreased (P < 0.0001) with 45% of dogs reaching QoL values described for healthy animals. Tolerability was good-to-excellent with only four dogs reporting treatment associated reversible adverse events.Conclusions and clinical importance -PEA-um appears to be effective and safe in reducing pruritus and skin lesions, and in improving QoL in dogs with moderate atopic dermatitis and moderate pruritus.

show abstract

Section: Discussionsupporting

confidence: 83%

Efficacy of ultra‐micronized palmitoylethanolamide in canine atopic dermatitis: an open‐label multi‐centre study

Noli¹,

Valle

Miolo

et al. 2015

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…The effectiveness of cyclosporine in atopic dermatitis treatment was previously confirmed by numerous research (Steffan et al 2003, Taszkun 2010, Kowalik et al 2011 and estimated to be 30-83% after 4-6 weeks of treatment. These findings are similar to ours.…”

Section: Discussionmentioning

confidence: 53%

“…Genetic factors, which manifest themselves in a strong breed and family predisposition to the disease, have been found to play a major role in its pathogenesis. A full pathogenesis is still unknown but it is certain that the disease can be attributed to immunological aberrations and skin barrier dysfunctions (Marshela et al 2006, 2010, Pin at al. 2008).…”

Section: Introductionmentioning

confidence: 99%

The influence of non-specific anti-pruritus treatment with cyclosporine A on transepidermal water loss (TEWL) in natural atopic dermatitis in dogs

Zając¹,

Szczepanik²,

Wilkołek³

et al. 2015

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Atopic dermatitis is a common allergic skin disease in dogs. Monitoring the progress of treatment and the assessment of the severity of disease symptoms are crucial elements of the treatment procedure. One of the common means of assessing the severity of the clinical signs of the disease is the CADESI 03. Research studies have pointed to a possibility of assessing the severity of skin lesions by means of measuring biophysical skin parameters such as TEWL, skin hydration and erythema intensity. The aim of the study was the assessment of changes in TEWL and CADESI values measured in ten different body regions during non-specific anti-pruritus treatment. The examination was performed on ten dogs with atopic dermatitis (age from 2.5 years to 7 years, mean age 3.8 years). The measurements were performed in the following body regions: the lumbar region, the right axillary fossa, the right inguinal region, the ventral abdominal region, the right lateral thorax region, the internal surface of the auricle, interdigital region of the right forelimb, cheek, bridge of nose and the lateral site of antebrachum. A statistically significant decrease in CADESI values was reported starting from the second week of treatment. In the case of the mean TEWL values, a fall was observed after one week of treatment in the ventral abdominal region and the interdigital region, after two weeks of treatment in the axillary fossa and the inguinal region, and after three weeks in the cheek and the lateral thorax region. There was no statistically significant decrease in TEWL values in the course of treatment in four other regions.

show abstract

“… As most signs of canine AD are expected to respond to oral glucocorticoids or oclacitinib, clinicians should reconsider alternative diagnoses and/or the presence of secondary complications (for example, skin infections, ectoparasitism, nonatopic food reactions etc…) if there is no rapid clinical benefit after treating atopic dogs with these drugs (SOR C). Basis for such recommendations: Additional studies, which used prednisone or prednisolone as positive treatment controls for comparison with oclacitinib (QOE 1) [ 11 ] or ciclosporin (QOE 2) [ 12 , 13 ], have confirmed the rapid efficacy of oral glucocorticoids for treatment of canine AD. Oclacitinib has been shown to reduce pruritus and clinical signs significantly better than placebo (QOE 1) [ 14 ] and as well as—or, at the 14 day time point, better than—prednisolone (QOE 1) [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Basis for such recommendations: Additional studies, which used prednisone or prednisolone as positive treatment controls for comparison with oclacitinib (QOE 1) [ 11 ] or ciclosporin (QOE 2) [ 12 , 13 ], have confirmed the rapid efficacy of oral glucocorticoids for treatment of canine AD. Oclacitinib has been shown to reduce pruritus and clinical signs significantly better than placebo (QOE 1) [ 14 ] and as well as—or, at the 14 day time point, better than—prednisolone (QOE 1) [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

et al. 2015

View full text Add to dashboard Cite

BackgroundIn 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document.ResultsThe treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD.ConclusionsThis first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-015-0514-6) contains supplementary material, which is available to authorized users.

show abstract

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

Cited by 6 publications

References 9 publications

Efficacy of ultra‐micronized palmitoylethanolamide in canine atopic dermatitis: an open‐label multi‐centre study

Efficacy of ultra‐micronized palmitoylethanolamide in canine atopic dermatitis: an open‐label multi‐centre study

The influence of non-specific anti-pruritus treatment with cyclosporine A on transepidermal water loss (TEWL) in natural atopic dermatitis in dogs

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

Contact Info

Product

Resources

About